Now is the time for (2R,6R)-hydroxynorketamine to be viewed independently from its parent drug

Pharmacol Biochem Behav. 2018 Dec:175:24-26. doi: 10.1016/j.pbb.2018.09.005. Epub 2018 Sep 7.

Authors

Shigeyuki Chaki¹, Jun-Ichi Yamaguchi²

Affiliations

¹ Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan. Electronic address: s-chaki@taisho.co.jp.
² Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.

PMID: 30201385
DOI: 10.1016/j.pbb.2018.09.005

No abstract available

Keywords: (2R,6R)-hydroxynorketamine; (R,S)-ketamine; Antidepressant; Treatment-resistant depression.

MeSH terms

Animals
Antidepressive Agents / chemistry*
Antidepressive Agents / pharmacokinetics
Antidepressive Agents / pharmacology*
Humans
Ketamine / analogs & derivatives*
Ketamine / chemistry
Ketamine / pharmacokinetics
Ketamine / pharmacology
Stereoisomerism

Substances

Antidepressive Agents
Ketamine
6-hydroxynorketamine